Quantitative Cell-Based Bioassays for Individual and Combination Immune Checkpoint Immunotherapy Targets
The human immune system is comprised of a complex network of
immune checkpoint receptors that are promising new immunotherapy
targets for the treatment of a variety of diseases including cancer and
autoimmune-mediated disorders.
Current methods used to measure the activity of antibody and other
biologics drugs designed to target immune checkpoint receptors rely on
primary human cells and measurement of functional endpoints such as
cell proliferation, cell surface marker expression, and cytokine
production. These assays are laborious and highly variable due to their
reliance on donor primary cells, complex assay protocols, and
unqualified assay reagents. As a result, these assays are difficult to
establish in quality-controlled drug development settings.
To overcome these challenges, we developed a suite of cell-based
bioluminescent reporter bioassays for individual and combination
immune checkpoint immunotherapy targets including:
• PD-1 (PD-L1 or PD-L2), CTLA-4, LAG-3, TIGIT, PD-1+TIGIT
• GITR, 4-1BB, CD40, OX40
These mechanism of action (MOA)-based bioassays are available in
“thaw-and-use” format and demonstrate high specificity, sensitivity, and
reproducibility. The bioassays are qualified according to ICH guidelines
and demonstrate the performance required for use in antibody
screening, potency testing, and stability studies.
immune checkpoint receptors that are promising new immunotherapy
targets for the treatment of a variety of diseases including cancer and
autoimmune-mediated disorders.
Current methods used to measure the activity of antibody and other
biologics drugs designed to target immune checkpoint receptors rely on
primary human cells and measurement of functional endpoints such as
cell proliferation, cell surface marker expression, and cytokine
production. These assays are laborious and highly variable due to their
reliance on donor primary cells, complex assay protocols, and
unqualified assay reagents. As a result, these assays are difficult to
establish in quality-controlled drug development settings.
To overcome these challenges, we developed a suite of cell-based
bioluminescent reporter bioassays for individual and combination
immune checkpoint immunotherapy targets including:
• PD-1 (PD-L1 or PD-L2), CTLA-4, LAG-3, TIGIT, PD-1+TIGIT
• GITR, 4-1BB, CD40, OX40
These mechanism of action (MOA)-based bioassays are available in
“thaw-and-use” format and demonstrate high specificity, sensitivity, and
reproducibility. The bioassays are qualified according to ICH guidelines
and demonstrate the performance required for use in antibody
screening, potency testing, and stability studies.
